Study type: In vivo/preclinical · Status: Verified against declared source
Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling.
Theranostics · 2019
Study scale: We further examined the expression of unphosphorylated β-catenin through immunohistochemical staining on two sets of human NSCLC tissue arrays containing high (>6,785 μg/L) (n=60) and low (≤6,785 μg/L) (n=19) levels of LL-37 in the serum.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Cramp knockout (Cramp-/-) mice previously described 5 were kindly provided by Prof.
Methods
Methods: The expression of LL-37 in the tissues and sera of patients with non-small cell lung cancer was determined through immunohistological, immunofluorescence analysis, and enzyme-linked immunosorbent assay.
Scale or participants
We further examined the expression of unphosphorylated β-catenin through immunohistochemical staining on two sets of human NSCLC tissue arrays containing high (>6,785 μg/L) (n=60) and low (≤6,785 μg/L) (n=19) levels of LL-37 in the serum.
Key findings
Rationale: Antimicrobial peptides, such as cathelicidin LL-37/hCAP-18, are important effectors of the innate immune system with direct antibacterial activity.
Limitations and uncertainty
Rationale: Antimicrobial peptides, such as cathelicidin LL-37/hCAP-18, are important effectors of the innate immune system with direct antibacterial activity.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.